Gov't authorizes COVID-19 vaccine from Pfizer and BioNTech

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine.

The Health Sciences Authority has authorised Pfizer and BioNTech SE’s updated COVID-19 vaccine tailored to the Omicron JN.1 variant, making Singapore the first Southeast Asian country to receive full approval.

The approval was based on manufacturing and non-clinical immunogenicity evaluation, leveraging on previous clinical data to support the safety and effectiveness of Pfizer-BioNTech’s COVID-19 vaccines.

The non-clinical data showed that the Omicron JN.1-adapted vaccine responds better against the circulating variant compared to the Omicron XBB.1.5-adapted vaccine.

The vaccine is expected to enhance protection against current strains, particularly for high-risk populations such as the elderly and individuals with pre-existing conditions.

Follow the link for more news on

Pfizer

COVID-19

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia